Eucrates Biomedical Acquisition Corp. Unit
| 10.02 | 0 | 0.00 | Vol - | 1Y Perf 1.01% |
| Apr 26th, 2023 15:59 DELAYED |
| BID | 0.00 | ASK | 0.00 | ||
| Open | 0.00 | Previous Close | 10.02 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | - | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.00 | Earnings Rating | — | |
| Market Cap | 103.71M | Earnings Date | - | |
| Alpha | 0.00 | Standard Deviation | 0.03 | |
| Beta | -0.06 |
Today's Price Range 0.000.00 | 52W Range 9.7610.63 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | - | ||
| 1 Month | - | ||
| 3 Months | - | ||
| 6 Months | -3.38% | ||
| 1 Year | 1.01% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | 2.52 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | 2.40 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | 2.27 | |||
Return on invested Capital Q | 0.38 | |||
Return on invested Capital Y | 0.25 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.50 | ||||
| 0.80 | ||||
| - | ||||
| 0.00 | ||||
| - | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 0 |
| Shares Outstanding | 10.35K |
| Shares Float | 10.35M |
| Trades Count | 0 |
| Dollar Volume | 0 |
| Avg. Volume | 8.36K |
| Avg. Weekly Volume | 13.67K |
| Avg. Monthly Volume | 9.26K |
| Avg. Quarterly Volume | 2.14K |
Eucrates Biomedical Acquisition Corp. Unit (NASDAQ: EUCRU) stock closed at 10.02 per share at the end of the most recent trading day (a 0.1% change compared to the prior day closing price) with a volume of 21.51K shares and market capitalization of 103.71M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Diversified Financial Services industry, Financial Services sector and employs 4 people. Eucrates Biomedical Acquisition Corp. Unit CEO is Parag Saxena.
The one-year performance of Eucrates Biomedical Acquisition Corp. Unit stock is 1.01%, while year-to-date (YTD) performance is 0.4%. EUCRU stock has a five-year performance of %. Its 52-week range is between 9.76 and 10.63, which gives EUCRU stock a 52-week price range ratio of %
Eucrates Biomedical Acquisition Corp. Unit currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of 2.40%, a ROC of 2.27% and a ROE of 2.52%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Eucrates Biomedical Acquisition Corp. Unit, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Eucrates Biomedical Acquisition Corp. Unit’s next earnings report date is -.
The consensus rating of Wall Street analysts for Eucrates Biomedical Acquisition Corp. Unit is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Eucrates Biomedical Acquisition Corp. Unit stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Eucrates Biomedical Acquisition Corp. Unit has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Eucrates Biomedical Acquisition Corp. Unit has a Neutral technical analysis rating based on Technical Indicators (ADX : 30.85, ATR14 : 0.08, CCI20 : -89.32, Chaikin Money Flow : 0.65, MACD : 0.00, Money Flow Index : 9.90, ROC : -1.09, RSI : 47.66, STOCH (14,3) : 1.61, STOCH RSI : 0.15, UO : 48.62, Williams %R : -98.39), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Eucrates Biomedical Acquisition Corp. Unit in the last 12-months were:
Eucrates Biomedical Acquisition Corp. Unit
Eucrates Biomedical Acquisition Corp is a blank check company.
CEO: Parag Saxena
Telephone: +1 212 710-5220
Address: 250 West 55th Street, New York 10019, NY, US
Number of employees: 4
